GOSI slashes SANED contribution rate to 1.5%    Jordan Records 3,493 New Cases of Coronavirus    Future Minerals Forum highlights role of the Kingdom and its future vision    Hajj Ministry: 10-day mandatory interval between two Umrahs applicable to foreign pilgrims too    SFDA organizes 'Coaching Day' event to support leadership development    National eLearning Center to hold conference on "eLearning for Human Capability Development"    Civil Defense urges all to be careful as inclement weather continues in some areas    COVID-19 cases number is unprecedented, but critical cases are lower than previous stages    Saudi Arabia qualifies for Beijing Winter Olympics in another first    Chopard ambassador Jacky Ickx in Riyadh    KSrelief Distributes More Than 63 Tons of Food Baskets in Taiz, Yemen    Saudi female engineer wins international award for inventing a chip that detects cancer    UAE Announces 3,067 New COVID-19 Cases, 3 deaths in Last 24 Hours    Governor of Riyadh Receives Ambassador of Qatar    Ministry of Health Starts Second Phase of Coronavirus Vaccination for Children Aged 5-11    Hostages freed after 10-hour stand-off at Texas synagogue    Police in Italy see red after being given pink facemasks    Djokovic to be deported after losing final Australia visa appeal    UN stands ready to provide support after volcano eruption and tsunami in Tonga    GCC Secretary General to Discuss Tomorrow in Brussels Ways to Strengthen GCC-EU Relations    "Hiking" Trail Events on Farasan Island Conclude    Palestinian Foreign Ministry: Int'l Silence on Israeli Settlement Destroys Two-State Solution    Saudi Pavilion at Expo 2020 Dubai celebrates 'Year of Saudi Coffee 2022'    Putin and Xi set to meet on opening day of Beijing Olympics    S. Korean president arrives in Dubai for economic diplomacy on Mideast swing    Saudi Arabia's box office jumps 95% in 2021, hits $238 million sales    Secretaries General of Local and Regional Federations in Asia Concludes Conference    Real Madrid to Face Athletic Bilbao in Riyadh Tomorrow in Final of Spanish Super Cup 2022    SAMF President Highly Commends Saudi Arabia Dakar Rally 2022    Makkah Governor Patronizes Closing Ceremony of Saudi Arabia Dakar Rally 2022    First edition of AlUla Art Residency closes with artists premiering contemporary works 'The Oasis Reborn'    At McDonald's, your favourite beef burgers are now hotter, tastier, and juicier    "Saudi Exports" Wins ISO Certificate for Business Continuity    Saudi Stock Market Index Closes High    ITFC Tops Bloomberg 2021 Global Islamic Financing League Tables as Best Bookrunner and Mandated Lead Arranger    IATA Renews International Accreditation of Saudi Academy of Civil Aviation    Reflections on celebration of Christmas    Royal Commission for AlUla to Hold Custodian of the Two Holy Mosques Endurance Cup 2022, Richard Mille AlUla Desert Polo    Saudi Arabia's Pavilion at Expo 2020 Dubai Organizes a Dance Theatrical Show for Children    Saudi Arabia rebuffs UN resolution on 'sexual orientation'    Kabir Khan eyes on joint Indian – Saudi film projects    Saudi Film Commission Announces Incentives for Local and International Producers    "Ithra" Unveils Winner of Ithra Prize for Arts at Diriyah Biennale    Bollywood superstar Salman Khan to dazzle Riyadh Season on Dec. 10    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Study: Oxford COVID-19 vaccine is safe and triggers response in adults over 56
Published in The Saudi Gazette on 19 - 11 - 2020

Phase 2 trials of Oxford University's COVID-19 vaccine in healthy older adults have found it is safe and provokes an immune response.
The university confirmed that the candidate vaccine it is developing with AstraZeneca showed similar safety and immunogenicity results in healthy older people (aged 56 and over) to those seen in adults aged 18-55 years.
Older people are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use is effective in this group.
The early-stage results, which they described as "promising" were published Thursday in The Lancet medical journal.
The phase 2 trial, which involved 560 adults including 240 over the age of 70, found that the vaccine causes few side effects and induces immune responses in both parts of the immune system in all age groups.
Results showed within 14 days of the first dose of vaccination it provoked a T cell response — it could find and attack cells infected with the virus — and caused an antibody response within 28 days of the booster jab.
Phase 3 trials, which involve thousands of participants, are ongoing to confirm these results, as well as how effective the vaccine is in protecting against infection with SARS-CoV-2 (the strain of the virus that causes coronavirus disease) in a broader range of people, including older adults with underlying health conditions, according to the vaccine's developers
"Immune responses from vaccines are often lessened in older adults because the immune system gradually deteriorates with age, which also leaves older adults more susceptible to infections," said study lead author, Professor Andrew Pollard from the University of Oxford.
"As a result, it is crucial that COVID-19 vaccines are tested in this group who are also a priority group for immunization."
Late-stage trial results will show if the Astra-Oxford vaccine can meet the standard set by front-runners Pfizer-BioNTech and Moderna.
Pfizer and BioNTech said Wednesday that the coronavirus vaccine they were developing has been proved 95 percent effective overall, with efficacy in adults over 65 years of age at 94 percent.
The US and German pharmaceuticals organizations said the candidate now met the safety criteria needed for emergency authorization.
US biotechnology company Moderna said on Monday that, based on preliminary data, their potential coronavirus vaccine has been deemed to be 94.5 percent effective at preventing people from getting the virus.
Trials for the Astra-Oxford vaccine candidate were paused in September after a participant fell ill.
They were restarted again after the company had investigated whether a vaccine recipient's "potentially unexplained" illness was a result of receiving the jab.
In large trials like this one, "it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety," the Oxford University said.
It did not disclose medical information about the illness that caused the trial to be put on hold, citing participant confidentiality.
Health experts, including the UK government's chief scientific adviser, Sir Patrick Vallance, have said pauses in drug trials are commonplace to ensure safety and effectiveness. — Courtesy Euro mews


Clic here to read the story from its source.